Association between the PPARalpha L162V polymorphism, plasma lipoprotein levels, and atherosclerotic disease in patients with diabetes mellitus type 2 and in nondiabetic controls.

MLA

Gouni-Berthold, Ioanna, et al. “Association between the PPARalpha L162V Polymorphism, Plasma Lipoprotein Levels, and Atherosclerotic Disease in Patients with Diabetes Mellitus Type 2 and in Nondiabetic Controls.” American Heart Journal, vol. 147, no. 6, June 2004, pp. 1117–24. EBSCOhost, https://doi.org/10.1016/j.ahj.2003.12.005.

APA

Gouni-Berthold, I., Giannakidou, E., Müller-Wieland, D., Faust, M., Kotzka, J., Berthold, H. K., & Krone, W. (2004). Association between the PPARalpha L162V polymorphism, plasma lipoprotein levels, and atherosclerotic disease in patients with diabetes mellitus type 2 and in nondiabetic controls. American Heart Journal, 147(6), 1117–1124. https://doi.org/10.1016/j.ahj.2003.12.005

Chicago

Gouni-Berthold, Ioanna, Eleni Giannakidou, Dirk Müller-Wieland, Michael Faust, Jörg Kotzka, Heiner K Berthold, and Wilhelm Krone. 2004. “Association between the PPARalpha L162V Polymorphism, Plasma Lipoprotein Levels, and Atherosclerotic Disease in Patients with Diabetes Mellitus Type 2 and in Nondiabetic Controls.” American Heart Journal 147 (6): 1117–24. doi:10.1016/j.ahj.2003.12.005.